文献速递造血干细胞移植与细胞治疗

多中心前瞻性随机安慰剂对照II/III期试验:抢先治疗急性移植物抗宿主病

A multicenter prospective, randomized, placebo-controlled phase II/III trial for preemptive acute graft-versus-host disease therapy.
PubMed 文献 · Leukemia · 2020-10-20

该研究评估尿液蛋白质组学特征(aGvHD_MS17)预测价值及抢先泼尼松龙治疗急性GVHD的效果。随机试验主要终点为随机化至移植后+100天之间II级aGvHD发生率,结果显示抢先泼尼松龙治疗未显著改变aGvHD发生率或严重程度(HR: 1.69, 95% CI: 0.66-4.32, P=0.27),且未增加复发(安慰剂组20.2% vs 泼尼松龙组14.0%,P=0.46),安慰剂组不良事件频率略高(64.4% vs 50%)。

要点

  • 抢先泼尼松龙治疗未显著降低II级aGvHD发生率(HR 1.69, P=0.27)。
  • 抢先泼尼松龙未增加复发率(14.0% vs 20.2%, P=0.46)。
  • 该策略在随机患者中显示可行且安全。

核心结论

  • 在aGvHD_MS17分类因子>0.1的异基因HSCT患者中,抢先泼尼松龙治疗未显著降低随机化至+100天II级aGvHD发生率或严重程度。
  • 抢先泼尼松龙治疗未增加复发,且不良事件频率在安慰剂组略高,显示该策略可行且安全。

研究设计与样本

  • 其余167例患者组成观察组。

主要发现

  • 随机患者中,抢先泼尼松龙治疗与安慰剂相比,aGvHD发生率或严重程度无显著差异(HR: 1.69, 95% CI: 0.66-4.32, P=0.27)。
  • 复发率在安慰剂组为20.2%,泼尼松龙组为14.0%(P=0.46)。
  • 不良事件频率安慰剂组为64.4%,泼尼松龙组为50%。

关键数值与推荐

  • 随机化标准:aGvHD_MS17分类因子>0.1。
  • 泼尼松龙剂量:2-2.5 mg/kg,治疗5天后逐渐减量。
  • 主要终点:随机化至HSCT后+100天之间II级aGvHD发生率。

临床怎么用

  • 对于aGvHD_MS17分类因子>0.1的异基因HSCT患者,抢先泼尼松龙治疗(2-2.5 mg/kg×5天)可行且安全,但未显著降低aGvHD发生率。
  • 该策略未增加复发风险,不良事件可接受。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Acute graft-versus-host disease (aGvHD) contributes to about 50% of transplant-related mortality (non-relapse mortality) after allogeneic hematopoietic stem cell transplantation (HSCT). Here the predictive value of a urinary proteomic profile (aGvHD_MS17) was tested together with preemptive prednisolone therapy. Two-hundred and fifty-nine of 267 patients were eligible for analysis. Ninety-two patients were randomized upon aGvHD_MS17 classification factor above 0.1 to receive either prednisolone (2-2.5 mg/kg, N = 44) or placebo (N = 47; N = 1 randomization failure) for 5 days followed by tapering. The remaining 167 patients formed the observation group. The primary endpoint of the randomized trial was incidence of aGvHD grade II between randomization and day +100 post HSCT. Analysis of the short-term preemptive prednisolone therapy in the randomized patients showed no significant difference in incidence or severity of acute GvHD (HR: 1.69, 95% CI: 0.66-4.32, P = 0.27). Prednisolone as preemptive treatment did not lead to an increase in relapse (20.2% in the placebo and 14.0% in the prednisolone group (P = 0.46)). The frequency of adverse events was slightly higher in the placebo group (64.4% versus 50%, respectively). Taken together, the results of the Pre-GvHD trial demonstrated the feasibility and safety of preemptive prednisolone treatment in the randomized patients.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Weissinger EM, Metzger J, Schleuning M, et al. A multicenter prospective, randomized, placebo-controlled phase II/III trial for preemptive acute graft-versus-host disease therapy. Leukemia. 2020. PMID: 33082512. doi:10.1038/s41375-020-01059-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。